Acute renal colic is probably the most excruciatingly painful event a person can endure. The pain is often described as being worse than childbirth, broken bones, gunshot wounds, burns, or surgery. Renal colic affects approximately 1.2 million people each year and accounts for approximately 1% of all hospital admissions in emergency and casualty ward. The pain generated by renal colic is primar...

Concomitant administration of certain fluoroquinolone antimicrobials and nonsteroidal antiinflammatory agents (NSAIDs) induces serious convulsion in humans. There are differences in convulsive activity among fluoroquinolones and in the potentiation of fluoroquinolone-induced convulsion among NSAIDs, but a comprehensive, quantitative comparison has not been carried out. This study evaluates the ...

BACKGROUND Nonsteroidal anti-inflammatory drugs (NSAIDs) are used in clinical practice as analgesics or anti-inflammatory drugs. Studies have implicated them in participating in permeability throughout various tissues such as the kidneys and lungs. OBJECTIVE The effect of NSAIDs on the pleural permeability and the underlying mechanisms whereby this effect is mediated were investigated. METH...

Objective: The aim of this study was to compare the postoperative analgesic effects of preoperative intravenous (i.v.) paracetamol, diclofenac sodium and lornoxicam (nonsteroidal anti-inflammatory drugs). Subjects and Methods: Sixty patients with impacted third molar who underwent surgical removal were randomly allocated into three groups: group P (n = 20), group D (n = 20) and group L (n = 20)...

Objective: The aim of this study was to compare the postoperative analgesic effects of preoperative intravenous (i.v.) paracetamol, diclofenac sodium and lornoxicam (nonsteroidal anti-inflammatory drugs). Subjects and Methods: Sixty patients with impacted third molar who underwent surgical removal were randomly allocated into three groups: group P (n = 20), group D (n = 20) and group L (n = 20)...

Lornoxicam (Lnxc), a novel type of non-steroidal antiinflammatory drug developed by comely, was first listed in Denmark in October 1997 (trade name xefo). Clinically, it is used to treat rheumatoid, rheumatoid arthritis and osteoarthritis. The Lnxc with low drug concentration has a short half-life [1] after oral administration, leading to much side effect and therapy activity tended to be worse...